SynthesisUpdates in surgery2025
The relationship between preoperative serum cystatin C levels and postoperative oncologic outcomes in patients with renal cell carcinoma: a systematic review and meta-analysis of 1641 patients.
Synthesis in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing number of studies have indicated that cystatin C (CysC) may serve as an effective indicator for predicting the prognosis of renal cell carcinoma (RCC). However, there was currently a lack of meta-analysis examining the influence of serum CysC on the prognosis of RCC. From April 2016 to June 2024, we ultimately selected five retrospective studies including 1641 participants to evaluate the effect of serum CysC on patients with RCC. All data were analyzed using Review Manager version 5.3. The research findings primarily focused on overall survival (OS) and disease-free survival (DFS). Both univariate and multivariate analyses were conducted to evaluate the results. Five studies involving a total of 1641 patients were selected based on predefined eligibility criteria. Univariate analysis revealed that serum CysC levels were significantly correlated with OS (P < 0.00001) and DFS (P = 0.02) in postoperative patients with RCC. Elevated serum CysC levels were considered a reliable predictor of poor prognosis in patients with RCC. Multivariate analysis indicated that high serum CysC levels were an independent risk factor for OS (P < 0.00001) and DFS (P = 0.006) in postoperative patients with RCC, remaining unaffected by other factors. Our research results indicated that elevated serum CysC levels were associated with reduced OS and DFS in patients with RCC. However, caution must be exercised before making recommendations as this interpretation was based on very few clinical studies and small samples.
Indexed as
Identifiers
40325333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.